ESCAPE Bio
South San Francisco · Founded 2015
About ESCAPE Bio
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $187.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2020)
- Website: https://www.e-scapebio.com
- Phone: 650-431-0100
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/escape-bio-72489 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.